A Pilot Study on the Combined Use of Cognitive Behavioral Therapy (CBT) and Milnacipran

简要总结

详细描述

Qualified participants will take part in a 21-week clinical research study entitled, "Drug and Talk Therapy for Fibromyalgia". We are doing this study to better understand how talk therapies, such as education and cognitive behavioral therapy (CBT), can improve the therapeutic benefits of drug for fibromyalgia. Savella ®, (milnacipran) is an FDA approved drug for fibromyalgia. The safety and efficacy of Savella has been established in two US-based clinical studies involving over 2,000 patients with fibromyalgia. Because Savella has already been shown to be effective when used in isolation to treat fibromyalgia, we are conducting the study to determine whether combination treatment (Savella + talk therapy) is more efficacious than just Savella alone or talk therapy alone. Volunteers will be randomized (like flipping a coin) on two different levels: 1. Each participate will be randomized into one of two groups for medication: One group will receive Savella and the other group will receive a placebo (no medicinal value). Both the medication and the placebo will look identical and subjects will not be told into which group they have been placed until the completion of the study. Each participants has 66% chance of receiving Savella and 34% chance of getting the placebo. 2. The second level of randomization will be to determine which type of talk therapies you will be assigned to. Subjects will be randomly assigned to receive educational instruction relevant to fibromyalgia, OR cognitive behavioral therapy which includes a workbook. Both talk therapies will be provided over the phone once a week for 8 weeks. Each phone session may last for 30 minutes. Importantly, both talk therapies can provide coping tools and information designed to help manage fibromyalgia symptoms. Study Overview: Subjects will be asked to visit the Fibromyalgia Clinical Research Center on five separate occasions: Initial Screening (today's visit), Week 1, Week 2, Week 9, and Week 21. VISIT 1: 1. Informed consent and initial screening questionnaire,physical assessment 2. Issue a 'pain score' wrist monitor with instructions to record current pain level three times a day for one week VISIT 2: 1. Submit your pain recording 2. Complete the self-assessment questionnaires via computer 3. Vital signs check 4. Undergo pain sensitivity testing 5. If qualified, subjects be randomized to receive Savella or placebo AND to receive education or cognitive behavioral therapy VISIT 3: 1. We will assess the subject's willingness to continue participation. 2. Review medication diary and medication side-effect checklist. 3. Schedule PHONE Therapy sessions: 8 thirty minute calls VISIT 4: 1. One week prior to this visit, subjects will receive a 'pain score' monitor in order to enter current pain levels three times a day for one week. Then report for this visit. 2. Review side effect checklist, medication diary. 3. Completion of self-assessment questionnaires via computer 4. Undergo pain sensitivity testing VISIT 5: 1. One week prior to this visit, subjects will receive a 'pain score' monitor in order to enter current pain levels three times a day for one week. Then report for this visit. 2. Review side effect checklist, medication diary. 3. Completion of self-assessment questionnaires via computer 4. Undergo pain sensitivity testing 5. Upon visit completion, participants will receive a reduced dose regimen of the medication along with written and verbal instructions to safely discontinue the study medication.

主要结局

次要结局

• Change in Evoked Pain Scores(Baseline and Week 21 clinic visits)
• Identification of Group Assignment(week 21)